Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

Eli Lilly (LLY) is poised to report Q2 earnings on August 7, with analysts projecting $5.56 EPS on $14.4 billion in sales. Bank of America Securities (BofA) has slightly increased its Q2 revenue and EPS forecasts, primarily driven by stronger Zepbound sales, and maintains a Buy rating with a $1,000 price target, citing the company's exceptional long-term growth potential and leading position in the GLP-1 market. The upcoming earnings call is expected to focus on key product performance, new drug launches, and potential impacts from U.S. drug pricing changes.

Analysis

Eli Lilly's upcoming second-quarter earnings release on August 7 is framed by heightened expectations, with analyst consensus projecting $14.4 billion in sales and $5.56 adjusted EPS. Bank of America has issued a slight, low single-digit upward revision to its Q2 revenue and EPS model, attributing the change to robust sales momentum from the obesity drug Zepbound. This short-term optimism is mirrored in BofA's long-term conviction, as it maintains a Buy rating and a $1,000 price target, citing Lilly's exceptional growth potential at what it considers a reasonable valuation. The firm's analysis points to a dominant and sustained market position for Lilly in the incretin/GLP-1 space, alongside key competitor Novo Nordisk. While BofA’s long-term forecasts for key pipeline drugs remain largely unchanged, it has tweaked its full-year EPS model to reflect 1.9% growth in 2025 followed by a minor 0.7% decrease in 2026. Investor attention during the earnings call will be on the performance of flagship drugs Mounjaro and Zepbound, early commercial traction for new launches like Kisunla, updates on pivotal clinical trials such as SURPASS-CVOT, and management's perspective on potential regulatory risks from U.S. drug pricing reforms.

Key Decisions for Investors

• Investors should closely watch the upcoming Q2 report for confirmation of Zepbound and Mounjaro sales performance, as this is the core driver underpinning the stock's positive sentiment and BofA's $1,000 price target.
• Look beyond the headline numbers for management's guidance on the pipeline, particularly updates on key clinical trials like SURPASS-CVOT and the commercial ramp-up of new drugs like Kisunla, which are critical for the long-term thesis.
• It is prudent to monitor any commentary on regulatory headwinds, such as U.S. drug pricing reforms or pharma-related tariffs, as these represent a key risk to the sector's profitability and could temper future growth expectations.
• Given the analyst's view of a reasonable valuation and significant upside to the price target, a strong earnings beat could reinforce the bullish case and warrant maintaining or adding to positions.